Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate
Foghorn Therapeutics Presents New Preclinical Data For Selective SMARCA2 Inhibitor FHD-909 And For Selective CBP, EP300 And ARID1B Degrader Programs
Foghorn Therapeutics To Share New Cancer Drug Data At Major Research Conference
Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $10 Price Target
Foghorn Therapeutics Q4 EPS $(0.34) Misses $(0.27) Estimate, Sales $9.247M Miss $9.500M Estimate
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $13 Price Target
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Deliver On Growth Plans?
Reported Friday, Foghorn Therapeutics Secures $50M Equity Financing, Advances Oncology Pipeline, And Extends $208.9M Cash Runway Into First Half Of 2028
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Foghorn Therapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $11 price target.
BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11
Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12
Foghorn Therapeutics Named Jeff Sacher As Treasurer And Interim CFO
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?
Guggenheim Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12
Foghorn Therapeutics (FHTX): Forecast 28.8% Revenue Growth Challenges Ongoing Loss Narrative
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.